Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonafarnib - Sentynl Therapeutics

Next Previous
Search
Drug Profile

Lonafarnib - Sentynl Therapeutics

Alternative Names: EBP 994; MK-6336; Sarasar; SCH-066336; SCH-66336; Zokinvy

Latest Information Update: 12 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer AnGes; Eiger BioPharmaceuticals, Inc.; Merck & Co; Schering-Plough
  • Class Amides; Antineoplastics; Antivirals; Benzene derivatives; Halogenated hydrocarbons; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progeria; Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Progeria
  • Phase III Hepatitis D
  • Discontinued Breast cancer; Cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Glioma; Leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 05 Jun 2024 Updated efficacy data from the phase III D-LIVR trial in Hepatitis D presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
  • 03 May 2024 Sentynl Therapeutics acquires lonafarnib from Eiger BioPharmaceuticals
  • 18 Jan 2024 Registered for Progeria in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top